Life Sciences

  • June 15, 2026

    DOJ Says NY Court Can't Block Texas Trans Records Probe

    The U.S. Department of Justice urged a New York federal court Monday to deny a request for an order barring the government from seeking transgender minor patients' medical records through a criminal subpoena issued by a Texas grand jury, arguing the court lacks jurisdiction.

  • June 15, 2026

    Squires Rejects 7 AIA Cases, Explains Earlier Tesla Decision

    U.S. Patent and Trademark Office Director John Squires has granted five patent challenges and rejected seven others, and he also issued a decision Monday explaining why he allowed a group of Tesla petitions to go ahead to the merits stage of review.

  • June 15, 2026

    Univ. Of Washington Beats Medical Prof's Bias Suit At Trial

    Jurors have cleared the University of Washington's medical school of liability in an anesthesiology professor's lawsuit alleging that she was unfairly ousted from a director role after complaining of discrimination and harassment, finding that the professor failed to sufficiently prove any of her three claims against the school.

  • June 15, 2026

    FTC Pulls OptumRx Insulin Price Case To Review Final Deal

    The Federal Trade Commission's third and final settlement resolving an in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes is in sight after the agency on Friday pulled from adjudication its allegations against UnitedHealth Group Inc.'s OptumRx to review a deal struck with staffers.

  • June 15, 2026

    $239M LabCorp Deal Illegally Shared Genetic Info, Suit Says

    Genetic testing company Invitae Corp. has been hit with proposed class privacy claims by an Illinois parent who says the company unlawfully disclosed its patients' genetic information to LabCorp after the laboratory testing giant bought Invitae out of bankruptcy.

  • June 15, 2026

    CareFirst Says Intent Standard Was Misread In Stelara Case

    CareFirst is arguing that a Virginia federal judge created a new standard for monopolization claims when he dismissed claims from the company's antitrust suit challenging Johnson & Johnson's protection of its immunosuppressive drug Stelara, arguing he misread a Fourth Circuit decision in ruling that monopolization requires a showing of specific intent.

  • June 15, 2026

    Mead Johnson Wins New Trial Over $60M NEC Formula Verdict

    An Illinois appellate panel has thrown out a $60 million jury verdict awarded to a mother claiming Mead Johnson's infant formula caused her premature baby to develop a fatal gut disease, saying the trial court erred in finding the company owed a duty to warn the mother and not just the infant's doctors, and allowing prejudicial evidence about Mead Johnson's profits.

  • June 15, 2026

    Wyo. Judge Nixes 3 Abortion Care Limits As Unconstitutional

    A Wyoming judge has struck down three state laws restricting abortion care, finding that the state failed to demonstrate it had a compelling interest in effectuating a 48-hour waiting period for abortions and requiring certain abortion facilities to be licensed as ambulatory surgical centers, among other restrictions.

  • June 15, 2026

    Nano-X Investors Sue Over Korea Plant Restructuring Hit

    Medical imaging company Nano-X Imaging Ltd. faces a proposed investor class action alleging it failed to tell investors that it had expanded its manufacturing operations beyond what customer demand justified, ultimately leading to a $17.5 million write-down.

  • June 15, 2026

    Hagens Berman Must Cover Fees After Misconduct Findings

    Hagens Berman Sobol Shapiro LLP must cover the fees and costs of a special master who alleged the firm committed misconduct in product liability litigation over the morning sickness drug thalidomide, a Pennsylvania federal judge has said.

  • June 15, 2026

    Mylan Investor Claims Atty Fees Too Much For 'Lost' Case

    An attorney and stockholder in the former Mylan NV objected to the attorneys' fees in a proposed $60 million class action settlement, telling a Pennsylvania federal judge Monday that the plaintiffs' lawyers effectively "lost" a suit that began with allegations of $5.1 billion in lost share value.

  • June 15, 2026

    Judge Gives First OK To $69M ChemoCentryx Deal

    A California federal judge has given the first green light to a $69 million settlement reached between investors and ChemoCentryx, resolving claims that the California-based pharmaceutical company overstated the efficacy of its newly developed treatment for autoimmune disease ANCA vasculitis.

  • June 12, 2026

    Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial

    A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and should pay $20.2 million in damages — the full amount Harbour was seeking.

  • June 12, 2026

    J&J Trial Over Doctor's Cancer Death Ends In Settlement

    A long-running dispute over whether Johnson & Johnson's baby powder caused the cancer that killed a Miami anesthesiologist concluded with a settlement just before closing arguments in a second trial after the first ended in a hung jury. 

  • June 12, 2026

    Disability Rights Orgs. Seek To Halt NY, Ill. 'Aid-In-Dying' Laws

    Disability rights organizations hit the governors of New York and Illinois with a pair of federal lawsuits seeking to stop new laws in each state from taking effect that would allow patients with terminal illnesses to seek a doctor's assistance in ending their lives.

  • June 12, 2026

    Zoetis Brass Face Derivative Suit Over Pet Meds Statements

    Directors and officers of animal health company Zoetis Inc. have been hit with shareholder derivative claims that they breached their fiduciary duties by concealing that safety warnings about one of its products and increasing competition were hurting the company's bottom line.

  • June 12, 2026

    Insider Trading Defense May Draw On 'Varsity Blues' Playbook

    After enlisting a crew of experienced attorneys, defendants charged in an insider trading case allegedly involving deal information stolen from huge law firms are preparing to use a strategy that could take some cues from the "Varsity Blues" case in the same Boston courthouse.

  • June 12, 2026

    Ex-Honeywell China GC Can't Bring US Bias Suit, Judge Says

    Honeywell International Inc. defeated a lawsuit alleging it unlawfully fired the vice president and general counsel at a Chinese subsidiary because she turned 55, with a North Carolina federal judge saying her employment contract requires the dispute to be handled in China.

  • June 12, 2026

    Taxation With Representation: Gibson Dunn, Davis Polk, S&C

    In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.

  • June 11, 2026

    AbbVie Loses Colorado 340B Drug Pricing Law Challenge

    A Colorado federal judge on Wednesday dismissed all of AbbVie Inc.'s claims against the state over its federal 340B drug pricing law, finding that the Colorado law isn't federally preempted and courts across the country have settled the issue.

  • June 11, 2026

    Ex-Pharma Exec Fights SEC 'Shadow Trading' Win At 9th Circ.

    An ex-Medivation Inc. executive urged the Ninth Circuit on Thursday to scrap a jury verdict finding him liable in the U.S. Securities and Exchange Commission's first-ever "shadow trading" case, arguing the company's own policies permitted the trades and affirming the verdict will allow companies to adopt vague trading policies.

  • June 11, 2026

    11th Circ. Seeks Fla., Ga. Justices' Input On Opioid Coverage

    The Eleventh Circuit on Thursday asked justices in Georgia and Florida to weigh in on whether commercial general liability insurers must defend and indemnify Publix Super Markets Inc. and a Georgia-based generic-drug wholesaler against suits claiming they improperly distributed opioids.

  • June 11, 2026

    Stop & Shop Parent Pays $40M On Inflated Drug Price Claims

    Stop & Shop's parent company will pay $40 million to resolve allegations it violated the False Claims Act by failing to report discounted prescription drug prices as "usual and customary" in claims submitted to federal Medicare, Medicaid and TRICARE programs, which resulted in overcharges, the U.S. Department of Justice announced Wednesday.

  • June 11, 2026

    Chinese Biopharma Sues Over National Security Threat Label

    Chinese pharmaceutical company WuXi AppTec sued the U.S. Department of Defense on Thursday, asking a D.C. federal court to set aside the agency's designation of the company as a Chinese military company, which it said was done "without a lawful or factual basis."

  • June 11, 2026

    23andMe To Pay $46.7M To Resolve Data Breach Claims

    The plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe has struck a deal to pay $46.7 million to data breach claimants, saying the move brings 23andMe one step closer to resolving the fallout of a massive data breach in 2023.

Expert Analysis

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here